Aggregation

No single method captures the full aggregation profile. SEC-MALS and SV-AUC approach aggregation assessment through very different physical means, bringing the strengths of each technique to the investigation.

Using orthogonal methods helps ensure the data reflects your product’s true aggregation profile and mitigates the risk of underestimating aggregate content due to sample loss or method-induced changes. Furthermore, the use of orthogonal methods for evaluation of a specific product characteristic is considered highly important by the regulatory authorities.

Yes. Aggregation is considered a critical quality attribute (CQA). Regulators expect a thorough understanding of aggregate content, especially for monoclonal antibodies and other biologics. Inadequate control of aggregation can raise red flags related to immunogenicity and product stability.

Information such as protein concentration, formulation buffer, pH, storage conditions, and any known aggregation issues helps us determine the most appropriate sample preparation procedure and ensure accurate interpretation of results.

Yes. Techniques like SV-AUC are especially effective at detecting small, soluble aggregates in the nanometre range. If you're concerned about early-stage aggregation or want to evaluate formulation stress responses, we can advise on the best combination of methods.

Factors such as pH, ionic strength, excipient choice, and freeze-thaw cycles can significantly influence aggregation. BioPharmaSpec can support pre-formulation and comparability studies by helping identify formulation conditions that minimise aggregation risk.

Absolutely. Demonstrating comparable aggregation profiles is essential for biosimilar submissions and is highlighted in the biosimilar guidelines from both the EMA and FDA. Our methods are regulatory-accepted and provide detailed, quantifiable data to support your comparability assessments.

Yes. While mAbs are a common focus, we routinely support a range of biologics, including enzymes, peptides, vaccines, oligonucleotides and fusion proteins, where aggregation can influence efficacy and safety.

Timeframes vary depending on the methods used and complexity of the molecule. SEC-MALS typically offers faster results, while SV-AUC requires longer run times. We’ll always provide estimated timelines and accommodate urgent project needs where possible.

Yes. Our methods for aggregation analysis can be qualified specifically for your product according to the ICH Q2(R2) guidelines if required.

Aggregation should definitely be one of the parameters that is investigated during any stability or forced degradation program. Since aggregation is recognized as a CQA, monitoring it over time under the relevant storage or stressing conditions is very important to understand changes that may take place in the product.